<DOC>
	<DOC>NCT01681940</DOC>
	<brief_summary>The overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis</brief_summary>
	<brief_title>Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis</brief_title>
	<detailed_description />
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<criteria>The subject must have participated in the phase 1 trial (EudraCT number: 201002208436) and phase 2a trial (EudraCT number: 201002208526) Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trialrelated activities (trialrelated activities are any procedures that would not have been performed during normal management of the subject) The subject and his/her guardian(s) must have the ability to comply with the protocol The subject cannot walk without support Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alphaMannosidosis History of bone marrow transplantation Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, would preclude participation in the trial. Pregnancy: Before the start of the treatment the investigators will decide whether or not there is a need for contraception. This assessment will be done through interviews with the patient and parents. The evaluation will be done continuously during the study Psychosis within the last 3 months Planned major surgery that, in the opinion of the investigator, would preclude participation in the trial Participation in other interventional trials testing IMP except for studies with Lamazym</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>